Comparison · NCT00724815-c3defb5e
NP101 Patch vs Placebo Patch: Phonophobia Free at Two Hours
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NP101 Patch vs Placebo Patch: Phonophobia Free at Two Hours. Trial comparisons, record NCT00724815-c3defb5e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00724815-c3defb5e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.553 | 0.488 | 0.616 | wilson | |
| Risk in group 2 | 0.39 | 0.329 | 0.455 | wilson | |
| Risk difference, group 1 minus group 2 | 0.163 | 0.071 | 0.251 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.42 | 1.16 | 1.73 | log | |
| Odds ratio, group 1 over group 2 | 1.93 | 1.33 | 2.81 | log | |
| Number needed to treat, for one more participant with the outcome on NP101 Patch than on Placebo Patch | 6.14 | 3.99 | 14.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NP101 Patch | The NP101 patch contained 86 mg of sumatriptan and was designed to deliver approximately 6.5 mg of sumatriptan over 4 hours. Patients were asked to treat one migraine episode with moderate to severe headache pain. | 125 | 226 | OG000 |
| Group 2 | Placebo Patch | The study placebo patch contained sodium chloride instead of sumatriptan which was delivered over 4 hours. Patients were asked to treat one migraine episode with moderate to severe headache pain. | 89 | 228 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Phonophobia Free at Two Hours
- Description
- Subjects who were phonophobia free and who had not received any rescue medication before their two-hour assessment.
- Time frame
- 2 hours post patch activation
- Population
- Per protocol, the intent-to-treat population was assessed.
Source ClinicalTrials.gov
Trial
- Title
- The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
- NCT number
- NCT00724815
- Phases
- PHASE3
- Conditions
- Migraine Disorders
- Interventions
- NP101 - Sumatriptan iontophoretic transdermal patch, Placebo
- Lead sponsor
- NuPathe Inc.
- Results first posted
- 2013-05-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00724815?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00724815-c3defb5e